Cystic Fibrosis (CF)
Novotech Publishes Analyst Report on Cystic Fibrosis Clinical Trial Landscape to Inform Biotech Research Planning 
April 10, 2024 22:33 ET | Novotech
The report presents a data-backed review of the Cystic Fibrosis (CF) funding landscape, trial density, and patient recruitment data.
Global Cystic Fibrosis Market
Global Cystic Fibrosis Market Analysis & 10 Year Forecast 2024-2034: By Drug Class, CFTR Modulators was the Highest Revenue-Grossing Segment in the Global Cystic Fibrosis Market in 2023
April 09, 2024 04:13 ET | Research and Markets
Dublin, April 09, 2024 (GLOBE NEWSWIRE) -- The "Global Cystic Fibrosis Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.The global cystic...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth Conference
March 05, 2024 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Transparency Market Research
Soft Mist Inhalers Market Size Projected to Grow at a 6.8% CAGR, Globally, by 2031 - Exclusive Report by Transparency Market Research, Inc.
February 29, 2024 01:45 ET | Transparency Market Research
Wilmington, Delaware, United States, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global soft mist inhalers market is projected to grow at a CAGR of 6.8% from 2022 to...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024
February 13, 2024 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma to Present at the DealFlow MicroCap Conference
January 23, 2024 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico
January 17, 2024 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Transparency Market Research
Respiratory Devices Market Size to be Worth USD 37.7 billion by 2031, with Notable CAGR of 6.1%| Transparency Market Research, Inc.
January 08, 2024 08:44 ET | Transparency Market Research
Wilmington, Delaware, United States, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global respiratory devices market is estimated to flourish at a CAGR of 6.1% from 2023...
ViaNautis.png
ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines
November 13, 2023 02:00 ET | ViaNautis Bio
ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver...
65f904ea-1192-4a36-be11-d574ccffe4fa.png
Spexis Announces Changes to the Executive Committee
November 01, 2023 02:20 ET | Spexis AG
Spexis Announces Changes to the Executive Committee